nach oben

Inflammation Research

Erschienen in:

01.04.2013 | Original Research Paper

Lipopolysaccharide-induced failure of the gut barrier is site-specific and inhibitable by growth hormone

verfasst von: Chao Yue, Wei Wang, Wei-Liang Tian, Qian Huang, Ri-Sheng Zhao, Yun-Zhao Zhao, Qiu-Rong Li, Jie-Shou Li

Erschienen in: Inflammation Research | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Gut barrier failure caused by endotoxemia is a life-threatening problem. The present study aimed to determine whether any specific intestinal site is highly correlated with gut barrier failure, and whether recombinant human growth hormone (rhGH) can ameliorate gut barrier failure in a rat model of endotoxemia.

Methods

Enterostomy tubes were surgically placed in adult male Sprague–Dawley rats three days before induction of endotoxemia by lipopolysaccharide (LPS) injection. Controls received no LPS. Rats were then randomly assigned to receive subcutaneous injections of rhGH (experimental, n = 30) or 0.9 % saline (control, n = 15) at 24, 48, or 72 h after LPS injection. Escherichia coli labeled with green fluorescent protein (GFP) were injected into the intestinal segment of all rats through the enterostomy tubes. The number of GFP-labeled E. coli detected in mesenteric lymph nodes was examined after 96 h. Apoptosis and proliferation rates of intestinal epithelial cells, and intestinal permeability were measured.

Results

Endotoxemia led to high mortality, compared with the control group, and rhGH treatment did not improve survival. Intestinal permeability, reflected by translocation rates of GFP-labeled E. coli, and apoptosis rates in the LPS-induced endotoxemia group were higher than those in the non-endotoxemia control group, and the endotoxemia ileum group had the highest rates of both bacterial translocation and apoptosis. The LPS+GH group had less bacterial translocation and apoptosis than the LPS-induced endotoxemia group. In contrast, the proliferation rates were lower in the LPS group compared to the LPS+GH group.

Conclusions

Endotoxemia can induce gut barrier failure in rats, and the ileum is the site of greatest risk. The GH can reduce the incidence of endotoxemia-induced gut barrier failure, but not the associated mortality.

Zhang L, Jin S, Wang C, et al. Histone deacetylase inhibitors attenuate acute lung injury during cecal ligation and puncture-induced polymicrobial sepsis. World J Surg. 2010;34(7):1676–83.PubMedCrossRef

Balzan S, de Almeida Quadros C, de Cleva R, et al. Bacterial translocation: overview of mechanisms and clinical impact. J Gastroenterol Hepatol. 2007;22(4):464–71.PubMedCrossRef

Garrett RE, Bar-Or D. Constipation critical illness and mortality. Gut-derived toxidromes—real and now imagined. Crit Care Med. 2008;36(9):2710–1.PubMedCrossRef

Zhang W, Gu Y, Chen Y, et al. Intestinal flora imbalance results in altered bacterial translocation and liver function in rats with experimental cirrhosis. Eur J Gastroenterol Hepatol. 2010;22(12):1481–6.PubMed

Song J, Wolf SE, Herndon DN, et al. Second hit post burn increased proximal gut mucosa epithelial cells damage. Shock. 2008;30(2):184–8.PubMedCrossRef

Yang R, Miki K, Oksala N, et al. Bile high-mobility group box 1 contributes to gut barrier dysfunction in experimental endotoxemia. Am J Physiol Regul Integr Comp Physiol. 2009;297(2):R362–9.PubMedCrossRef

Enomoto N, Takei Y, Yamashina S. Burn injury sensitizes rat Kupffer cells via mechanisms dependent on gut-derived endotoxin. J Gastroenterol. 2004;39(12):1175–81.PubMedCrossRef

Crouser ED, Julian MW, Weinstein DM, et al. Endotoxin-induced ileal Mucosal Injury and Nitric Oxide Dysregulation Are Temporally Dissociated. Am J Respir Crit Care Med. 2000;161(5):1705–12.PubMed

Duska F, Fric M, Waldauf P, et al. Frequent intravenous pulses of growth hormone together with glutamine supplementation in prolonged critical illness after multiple trauma: effects on nitrogen balance, insulin resistance, and substrate oxidation. Crit Care Med. 2008;36(6):1707–13.PubMedCrossRef

10.

Branski LK, Herndon DN, Barrow RE, et al. Randomized controlled trial to determine the efficacy of long-term growth hormone treatment in severely burned children. Ann Surg. 2009;250(4):514–23.PubMed

11.

Gomez-de-Segura IA, Prieto I, Grande AG, et al. Growth hormone reduces mortality and bacterial translocation in irradiated rats. Acta Oncol. 1998;37(2):179–85.PubMedCrossRef

12.

Vazquez I, Gomez-de-Segura IA, Grande AG, et al. Protective effect of enriched diet plus growth hormone administration on radiation-induced intestinal injury and on its evolutionary pattern in the rat. Dig Dis Sci. 1999;44(11):2350–8.PubMedCrossRef

13.

Eizaguirre I, Aldazabal P, Barrena MJ, et al. Effect of growth hormone on bacterial translocation in experimental short-bowel syndrome. Pediatr Surg Int. 1999;15(3–4):160–3.PubMedCrossRef

14.

Samel Stephan, Keese Michael, Kleczka Martha. Microscopy of bacterial translocation during small bowel obstruction and ischemia in vivo–a new animal model. BMC Surg. 2002;2:6.PubMedCrossRef

15.

Wilson TH, Wiseman G. The use of sacsof everted small intestine for the study of the transference of substances from the mucosal to serosal surface. J Physiol. 1954;123(1):116–25.PubMed

16.

Tawadrous Z, Delude RL, Fink MP. Resuscitation from hemorrhagic shock with Ringer’s ethyl pyruvate solution improves survival and ameliorates intestinal mucosal hyperpermeability in rats. Shock. 2002;17(6):473–7.PubMedCrossRef

17.

Chiu CJ, McArdle AH, Brown RA, et al. Intestinal mucosal lesion in low-flow states. A morphological, hemodynamic, and metabolic reappraisal. Arch Surg. 1970;101(4):478–83.PubMedCrossRef

18.

Ouhtit A, Muller HK, Davis DW, et al. Temporal events in skin injury and the early adaptive responses in ultraviolet-irradiated mouse skin. Am J Pathol. 2000;156(1):201–7.PubMedCrossRef

19.

Tascilar N, Irkorucu O, Tascilar O, et al. Bacterial translocation in experimental stroke: what happens to the gut barrier? Bratisl Lek Listy. 2010;111(4):194–9.PubMed

20.

Velasco N. Gut barrier in the critically ill patient. Facts and trends. Rev Med Chil. 2006;134(8):1033–9.PubMed

21.

Magnotti LJ, Deitch EA. Burns, bacterial translocation, gut barrier function and failure. Burn Care Rehabil. 2005;26(5):383–91.CrossRef

22.

Caine WR, Metzler-Zebeli BU, McFall M, et al. Supplementation of diets for gestating sows with zinc amino acid complex and gastric intubation of suckling pigs with zinc-methionine on mineral status, intestinal morphology and bacterial translocation in lipopolysaccharide-challenged early-weaned pigs. Res Vet Sci. 2009;86(3):453–62.PubMedCrossRef

23.

Deitch EA, Taylor M, Grisham M. Endotoxin induces bacterial translocation and increases xanthine oxidase activity. J Trauma. 1989;29(12):1679–83.PubMedCrossRef

24.

Mosenthal AC, Xu D, Deitch EA. Elemental and intravenous total parenteral nutrition diet-induced gut barrier failure is intestinal site specific and can be prevented by feeding nonfermentable fiber. Crit Care Med. 2002;30(2):396–402.PubMedCrossRef

25.

Fukushima R, Gianotti L, Alexander JW. The primary site of bacterial translocation. Arch Surg. 1994;129(1):53–8.PubMedCrossRef

26.

Powell DW. Barrier function of epithelia. Am J Physiol. 1981;241(4):G275–88.PubMed

27.

Wiest R, Rath HC. Bacterial translocation in the gut. Best Pract Res Clin Gastroenterol. 2003;17(3):397–425.PubMedCrossRef

28.

Pritts TA, Moon MR, Wang Q, et al. Activation of NF-kappa B varies in different regions of the gastrointestinal tract during endotoxemia. Shock. 2000;14(2):118–22.PubMedCrossRef

29.

Parikh AA, Moon MR, Pritts TA, et al. IL-1α induction of NF-κB activation in human intestinal epithelial cells is independent of oxyradical signaling. Shock. 2000;13(1):8–13.PubMedCrossRef

30.

Uronen-Hansson H, Allen ML, Lichtarowicz-Krynska E, et al. Growth hormone enhances proinflammatory cytokine production by monocytes in whole blood. Growth Horm IGF Res. 2003;13(5):282–6.PubMedCrossRef

31.

Tripathi A, Sodhi A. Growth hormone-induced production of cytokines in murine peritoneal macrophages in vitro: role of JAK/STAT, P13K, PKC and MAP kinases. Immunobiology. 2009;214(6):430–40.PubMedCrossRef

32.

Kappel M, Hansen MB, Diamant M, et al. In vitro effects of human growth hormone on the proliferative responses and cytokine production of blood mononuclear cells. Horm Metab Res. 1994;26(12):612–4.PubMedCrossRef

33.

Elsasser TH, Fayer R, Rumsey TS, et al. Recombinant bovine somatotropin blunts plasma tumour necrosis factor-a, cortisol, and thromboxane-B2 responses to endotoxin in vivo. Endocrinology. 1994;134(3):1082–8.PubMedCrossRef

34.

Wang P, Li N, Li JS. The role of endotoxin, TNF-alpha and IL-6 in inducing the state of growth hormone insensitivity. World J Gastroenterol. 2002;8(3):531–6.PubMed

35.

Liao W, Rudling M, Angelin B. Growth hormone potentiates the in vivo biological activities of endotoxin in the rat. Eur J Clin Invest. 1996;26(3):254–8.PubMedCrossRef

36.

Takala J, Ruokonen E, Webster NR. Increased mortality associated with growth hormone treatment in critically ill patients. N Engl J Med. 1999;341(11):785–92.PubMedCrossRef

37.

Jeschke MG, Finnerty CC, Kulp GA, et al. Combination of recombinant human growth hormone and propranolol decreases hypermetabolism and inflammation in severely burned children. Pediatr Crit Care Med. 2008;9(2):209–16.PubMedCrossRef

38.

Leaman DW, Leung S, Li X, et al. Regulation of STAT-dependent pathways by growth factors and cytokines. FASEB J. 1996;10(14):1578–88.PubMed

39.

Gilpin DA, Hsieh CC, Kuninger DT, et al. Effect of thermal injury on the expression of transcription factors that regulate acutephase response genes: The response of C/EBP alpha, C/EBP beta, and C/EBP delta to thermal injury. Surgery. 1996;119(6):674–83.PubMedCrossRef

40.

Haeffner A, Thieblemont N, Deas O, et al. Inhibitory effect of growth hormone on TNF-alpha secretion and nuclear factor-kappaB translocation in lipopolysaccharide-stimulated human monocytes. J Immunol. 1997;158(3):1310–4.PubMed

41.

Dejkhamron P, Thimmarayappa J, Kotlyarevska K, et al. Lipopolysaccharide (LPS) directly suppresses growth hormone receptor (GHR) expression through MyD88-dependent and-independent Toll-like receptor-4/MD2 complex signaling pathways. Mol Cell Endocrinol. 2007;274(1–2):35–42.PubMedCrossRef

Titel: Lipopolysaccharide-induced failure of the gut barrier is site-specific and inhibitable by growth hormone
verfasst von: Chao Yue
Wei Wang
Wei-Liang Tian
Qian Huang
Ri-Sheng Zhao
Yun-Zhao Zhao
Qiu-Rong Li
Jie-Shou Li
Publikationsdatum: 01.04.2013
Verlag: SP Birkhäuser Verlag Basel
Erschienen in: Inflammation Research / Ausgabe 4/2013
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-013-0593-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

CKD bei Diabetes: Neuheiten und Zukunftsaussichten

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Jeder Mensch mit Diabetes muss auf eine chronische Nierenerkrankung gescreent werden – diese neue Empfehlung spricht die KDIGO aus. Die Therapie erfolgt individuell und je nach Szenario mit verschiedenen Substanzklassen. Künftig kommt wahrscheinlich, neben RAS-Hemmung, SGLT2-Inhibition und nsMRA, eine vierte Therapiesäule hinzu.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

SHPS-1 and a synthetic peptide representing its ITIM inhibit the MyD88, but not TRIF, pathway of TLR signaling through activation of SHP and PI3K in THP-1 cells

Anti-inflammatory effect of quinoline alkaloid skimmianine isolated from Ruta graveolens L.

Identification of macrophage genes responsive to extracellular acidification

Endothelin-3 at low concentrations attenuates inflammatory responses via the endothelin B2 receptor

Overexpression of histamine H4 receptors in the kidney of diabetic rat